Stock comparison
ResMed
TG Therapeutics
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
RMD
ResMed
Market cap
$29.57B
Sector
Healthcare
TGTX
TG Therapeutics
Market cap
$6.51B
Sector
Healthcare
Overall winner
ResMed RMD
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | RMD | TGTX | Winner |
|---|---|---|---|
| Warren Buffett | 64C | 42D | RMD |
| Benjamin Graham | 67B | 54C | RMD |
| Philip Fisher | 67B | 50C | RMD |
| Peter Lynch | 50C | 84A | TGTX |
| Joel Greenblatt | 39D | 55C | TGTX |
| Charlie Munger | 61C | 44D | RMD |
| Terry Smith | 65B | 37D | RMD |
Side-by-side metrics
| Metric | RMD | TGTX |
|---|---|---|
| Market cap | $29.57B | $6.51B |
| P/E (TTM) | 19.6x | 13.3x |
| EV/EBIT | 17.1x | 55.3x |
| ROIC (TTM) | 19.63% | 11.13% |
| Gross margin | 61.69% | 83.04% |
| Net margin | 27.44% | 65.95% |
| Revenue CAGR 5y | 12.64% | 2.1% |
| EPS CAGR 5y | 30.73% | - |
| Debt / Equity | 0.1x | 1.3x |
| Dividend yield | 1.14% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
RMD leads on
- Dividend yield1.14%vs 0.0%+100%
- Debt / Equity0.1xvs 1.3x+90%
- Market cap$29.57Bvs $6.51B+78%
- EV/EBIT17.1xvs 55.3x+69%
TGTX leads on
- Revenue CAGR 5y2.1%vs 12.64%+94%
- Net margin65.95%vs 27.44%+58%
- P/E (TTM)13.3xvs 19.6x+32%
- Gross margin83.04%vs 61.69%+26%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.